atl1102 a clear winner

THIS IS WHY ATL1102 WILL BE A CLEAR WINNER FOR ANP.
REVENUE FOR 2016 $8.5 BILLION...[dark horse as previously posted]re STEM CELL GROWTH MARKET.




STEM CELL MARKET ANALYSIS FACT SHEET
• Stem Cell Company Revenues
o 2005: $ 974,000
o 2006: $ 16,405,000
o 2007: $ 36,856,000 estimated
o 2016: $8.5 billion estimated (new forecast to be released at Stem Cell
Summit on Feb. 12)
• Largest Suppliers of Stem Cell Therapies (Ranked in order of revenues
generated from the sale of stem cell therapies or related products)
o Blackstone Medical (a subsidiary of Orthofix Inc.)
o Osiris Therapeutics
o NuTech Medical
o ViaCell
o Aastrom Biosciences
o Cytori
o Geron
o Stem Cell Inc.
o BioE
• Estimated Number of Companies Developing Stem Cell Products
200+ worldwide
• Current Applications for Stem Cell Products
o Replacement for bone harvesting in spine fusion surgery
o Bone growth and void fill in fresh fractures
o Bone growth and void fill in non-union fractures
• Stem Cell Products Expected to be Approved by the FDA in the
Coming 36 Months
o Prochymal (treatment for graft vs. host disease)
o Two (possibly three) treatments for damaged heart muscle due to
heart disease
o Chondrogen (repair of knee cartilage)
• Market for Stem Cell Products
o Patient population in the United States for whom existing stem cell
therapies are applicable: 2.5 million +
Exhibit SC-1: Stem Cell Therapy Market, US, 2005-2016 $in 000s
Year
Annual Sales
est Growth
2005 $900
2006 $16,405 1722.8%
2007 $36,856 124.7%
2008 $146,085 296.4%
2009 $303,496 107.8%
2010 $707,332 133.1%
2011 $1,331,515 88.2%
2012 $2,335,116 75.4%
2013 $3,422,513 46.6%
2014 $4,741,545 38.5%
2015 $6,346,551 33.8%
2016 $8,476,845 33.6%
Stem Cell Therapy Sales 2005-2016
$ in thousands
$900 $16,405 $36,856 $146,085 $303,496
$707,332
$1,331,515
$2,335,116
$3,422,513
$4,741,545
$6,346,551
$8,476,845
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Year
Annual Sales
o Number of patients treated in 2006 the United States with stem cell
products for orthopedic, cardiovascular, dental, aesthetic, oncologic
or other indications: 5,900
o Market value of all public stem cell companies: $1.655 billion
o The most common type of commercial stem cell: An adult stem cell
derived from bone marrow
• Other Facts:
o Each stem cell product is typically assayed by its supplier, and the
number of viable stem cells is counted. A single dose of adult stem
cells for therapeutic use usually has a minimum of 104 million viable
stem cells.
o The most common source of commercial stem cells in the United
States is donor-derived adult stem cells.
o Donor-derived adult stem cells are available as either minimally
manipulated donated tissues or as cultured donor cells.
o Stem cell therapies are likely to be disruptive treatments for the
following medical sectors:
• Total knee implants
o Stem cell therapies that repair worn articular or
meniscus cartilage will delay and potentially
reduce the need for total knee replacement
surgery
• Sports medicine
o Stem cell therapies will extend the continuum of
care for “weekend warriors.” It is highly likely that
stem cell therapies will become the standard of
care for torn meniscus or damaged articular
cartilage
• Heart muscle repair following heart attacks
• To improve flow of blood by stimulating growth of new
capillaries and vessels to the heart muscle
• Use of bone marrow transplants
o Stem cell therapies significantly reduce the effects
of graft vs. host disease in patients with
transplants.
• Treating the broad range of inflammation in the human
body